血管前置的超声筛查:系统综述与Meta分析
该系统综述与Meta分析纳入19项队列研究、779845例妊娠和505例血管前置病例,评估标准化孕中期超声筛查联合孕晚期超声确认的产前检出率与围产期存活率。汇总敏感度和特异度均为1.00(95%CI 0.99-1.00和1.00-1.00,I²=0%),围产期存活率汇总为98.15%(95%CI 88.30%-100.00%,I²=0%)。作者认为标准化筛查与高检出率和高围产期存活率相关,假阳性和假阴性率极低。
要点
- 标准化孕中期超声筛查联合孕晚期确认的汇总敏感度为1.00(95%CI 0.99-1.00,I²=0%)。
- 汇总特异度为1.00(95%CI 1.00-1.00,I²=0%),基于774937例妊娠和11例假阳性。
- 产前诊断病例的围产期存活率汇总为98.15%(95%CI 88.30%-100.00%,I²=0%)。
核心结论
- 标准化血管前置筛查与高检出率和高围产期存活率相关,假阳性和假阴性率极低。
- 这些发现为标准化血管前置筛查提供了有力依据。
研究设计与样本
- 系统综述与Meta分析,检索PubMed/MEDLINE、Web of Science、Embase、Global Health和Global Index Medicus从建库至2024年2月16日。
- 纳入实施标准化孕中期超声筛查方案(普遍性或针对性)、经孕晚期超声确认并在分娩时验证、持续至少1年的队列研究。
- 共纳入19项研究,涵盖779845例妊娠和505例血管前置病例(1/1544)。
- 采用QUADAS-2评估偏倚风险,使用固定效应模型进行Meta分析,异质性用卡方、τ²和I²统计量评估。
主要发现
- 505例血管前置病例中494例(97.8%)为产前诊断。
- 标准化孕中期超声筛查联合孕晚期确认的汇总敏感度为1.00(95%CI 0.99-1.00;I²=0%)。
- 汇总特异度为1.00(95%CI 1.00-1.00;I²=0%),基于774937例妊娠和11例假阳性。
- 产前诊断病例的围产期存活率范围为87.5%至100%,汇总存活率为98.15%(95%CI 88.30%-100.00%;I²=0%)。
- 排除高偏倚风险研究后结果保持一致,未发现发表偏倚证据。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the prenatal detection of vasa previa and perinatal survival in studies that implemented standardized protocols of prospective second-trimester ultrasound screening protocols followed by ultrasound confirmation in the third trimester. DATA SOURCES: PubMed/MEDLINE, Web of Science, Embase, Global Health, and Global Index Medicus were searched from inception to February 16, 2024. STUDY ELIGIBILITY: We included cohort studies that implemented standardized second-trimester ultrasound protocols-either universal or targeted-for vasa previa screening, with third-trimester ultrasound confirmation and verification at delivery, over at least 1 year. Eligible studies reported both the total number of pregnancies screened and the number of confirmed vasa previa cases. Protocols included assessment of placental cord insertion, cervical region imaging, and transvaginal color Doppler in at-risk patients. We excluded first-trimester-only screening, case reports, reviews, conference abstracts, and overlapping populations. STUDY APPRAISAL AND SYNTHESIS METHODS: Two reviewers independently screened studies and extracted data, with discrepancies resolved by consensus. Risk of bias was assessed using Quality Assessment of Diagnostic Accuracy Studies, version 2 (QUADAS-2). Meta-analyses of sensitivity, specificity, and perinatal survival were conducted using fixed effects models with inverse-variance weighting using R version 4.4.0 (R Core Team, 2024). Heterogeneity was assessed with chi-square, τ2, and I2 statistics. Sensitivity analyses excluded studies with high risk of bias. Publication bias was evaluated using funnel plots and Egger's test. RESULTS: Of 1817 publications, 19 met inclusion criteria, encompassing 779,845 pregnancies and 505 vasa previa cases (1 in 1544). Of these, 494 (97.8%) were diagnosed prenatally. The pooled sensitivity of standardized second-trimester ultrasound screening-with third-trimester confirmation-was 1.00 (95% confidence interval, 0.99-1.00; I2=0%), and specificity was also 1.00 (95% confidence interval: 1.00-1.00; I2=0%), based on 774,937 pregnancies and 11 false positives. Perinatal survival among prenatally diagnosed cases ranged from 87.5% to 100%, with a pooled survival rate of 98.15% (95% confidence interval, 88.30% to 100.00%; I2=0%). Results remained consistent after excluding studies at high risk of bias. No evidence of publication bias was found. CONCLUSION: Standardized screening for vasa previa is associated with a high detection rate and high perinatal survival, with minimal false positive and false negative rates. These findings make a strong case for standardized screening for vasa previa.
引用
- Donovan B, Bonanni G, Javinani A, et al. Ultrasound screening for vasa previa: a systematic review and meta-analysis. Am J Obstet Gynecol. 2025. PMID: 40783118. doi:10.1016/j.ajog.2025.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。